GSK (GlaxoSmithKline) is a global biopharmaceutical company headquartered in the United Kingdom, with a significant presence in the European Union. GSK’s mission is to unite science, technology, and talent to get ahead of disease, aiming to positively impact the health of 2.5 billion people over the next decade. The company prioritizes innovation in vaccines and specialty medicines, focusing on infectious diseases, HIV, oncology, and immunology. GSK’s robust research and development (R&D) capabilities and manufacturing footprint in the EU enable it to play a pivotal role in shaping public health policies and advancing medical science in the region.
Since its registration with the EU Transparency Register in January 2009, GSK has actively engaged with EU institutions, advocating for policies that foster innovation, improve access to medicines, and address public health challenges such as antimicrobial resistance and pandemic preparedness. GSK’s lobbying efforts target a range of EU legislative files, including pharmaceutical legislation, health data regulations, the EU AI Act, and trade-related directives. The company is committed to transparency and ethical standards, adhering to both the Transparency Register Code of Conduct and the EFPIA Codes.
GSK’s Brussels office coordinates its EU affairs, while also participating in numerous trade associations and think tanks. The company maintains a high level of engagement with EU policymakers, as evidenced by its regular meetings with Commissioners, Directors-General, and other key officials. GSK’s lobbying activities are supported by a dedicated team of lobbyists, several of whom hold or have held European Parliament accreditations. The company also collaborates with intermediaries such as FTI Consulting Belgium to further its advocacy objectives.
Financially, GSK consistently reports substantial annual lobbying expenditures, reflecting its commitment to influencing EU policy in alignment with its business and public health goals. Its networking activities span a wide array of industry associations and business chambers, reinforcing its influence and collaborative approach within the EU ecosystem. GSK’s lobbying record demonstrates a sustained and strategic effort to shape the policy environment in which it operates, always with a focus on advancing healthcare outcomes and supporting innovation in the pharmaceutical sector
